Procedures
visceral disease
Randomization was 1:1, using visceral disease and hormone receptor status to stratify patients to pertuzumab (840 mg loading dose, followed by 420 mg every 3 weeks), trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks), and docetaxel (75 mg/mAfter the primary analysis, patients could cross over from the placebo arm to the pertuzumab arm due to pertuzumab showing a clinically significant improvement over placebo.